A study carried out by researchers at the National Institutes of Health and colleagues found that, unlike many other cell growth regulators, MYC does not turn genes on or off, but instead boosts the expression of genes that are already turned on.
These findings, which will be published in Cell on Sept. 28, could lead to new therapeutic strategies for some cancers.
“We carried out a highly sophisticated analysis of MYC activity in cells, but came away with a simple rule. MYC is not a power switch but a universal amplifier,” said co-lead study author Keji Zhao, Ph.D., director of the Systems Biology Center at the NIH’s National Heart, Lung, and Blood Institute (NHLBI). “This discovery offers a unifying idea of how and why abnormal levels of MYC are found in so many different cancer types, such as breast cancer, lung cancer, and several blood cancers.”
“MYC is much like the volume control of a music player,” added co-lead David Levens, M.D., Ph.D., a senior investigator in the Laboratory of Pathology at the National Cancer Institute (NCI), also part of NIH. “If you’re listening to opera, for example, adding more MYC will make the opera louder, but it won’t change the program to rap. And if you have only silence, MYC will just give you more silence.”
Both researchers noted that this new understanding of MYC function could influence future treatment efforts for MYC-associated tumors. They suggest that trying to limit MYC activity, or turning down the volume just the right amount, would be a better strategy than using targeted chemotherapy to try to eliminate all MYC activity.
MYC aids in cell activation, a process in which cells mature and divide quickly. During an immune response, for example, white blood cells are activated to help fight infections. If activation isn’t properly regulated, then cells can start growing out of control and result in cancer. Researchers have known that abnormally high levels of MYC can lead to cancer, but until now, no one had been able to explain how it can lead to so many different cancers.
Zhao, Levens, and their colleagues used a specially designed fluorescent protein that allowed them to track MYC in white blood cells in a lab dish. They chose white blood cells, specifically B cells and T cells that fight infections, because they are frequently affected by abnormal MYC and can transform into lymphoma and myeloma cells.
The team exposed the B and T cells to foreign toxins to stimulate an immune response and activate the fluorescent MYC. The researchers could then examine the cells at different time points and see which genes the MYC proteins seemed to affect.
The analysis revealed that MYC didn’t prefer any specific type of gene. Instead, MYC proteins were present at nearly every gene that was already expressed, or turned on. The researchers also noticed that the amount of MYC at each expressed gene correlated with how active that gene was prior to immune stimulation. The more active the gene, the more MYC gathered there. MYC appeared to amplify productivity relative to the initial expression levels where it gave a small boost to genes with low activity and a big boost to genes with high activity.
The researchers validated the idea of MYC as a universal amplifier by developing a set of B cells that did not produce functional MYC. When they were stimulated, the total cellular amount of RNA—an indicator of how much protein is being made—did not rise. When normal B cells were activated, the total cellular RNA did rise.
The research team then conducted the same analysis in embryonic stem cells and got similar results.
In addition to the research teams at the NHLBI and NCI, scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, also part of the NIH, and at St. Jude Children’s Research Hospital in Memphis, Tenn., contributed to this study.
For more information or to schedule an interview, contact the NHLBI Communications Office at 301-496-4236 or firstname.lastname@example.org or the NCI Office of Media Relations at 301-496-6641 or email@example.com.
# # #
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov.
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at http://www.cancer.govor call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH…Turning Discovery Into Health
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.